about
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.Ibrutinib in previously treated Waldenström's macroglobulinemia.Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaTargeting NF-kappaB in Waldenstrom macroglobulinemiaThalidomide and rituximab in Waldenstrom macroglobulinemiaThe genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesisHyperviscosity-related retinopathy in waldenstrom macroglobulinemia.Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.Novel agents in the treatment of Waldenström's macroglobulinemia.CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth.HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.Future therapeutic options for patients with Waldenström macroglobulinemia.Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia.Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database.Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling.Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia.CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.Clinical responses to sildenafil in Waldenstrom's macroglobulinemia.Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia.Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes.Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia.
P50
Q27851888-1CB65B2E-DCA1-452B-B5EE-C2B03553F836Q27853148-819268D9-F12E-422D-8B0F-3A2FF720E171Q28237372-C3B6DAD0-66EC-4445-94AE-18BDECC7FB9CQ28272373-604236F2-DAC1-4F1E-90D8-E628DDA10AAFQ28291293-B43333E4-70A3-47EF-97D7-C5432C030CAAQ28304614-7FD93C8E-9BEF-438B-B7A9-DE0ADFA88FF7Q33263486-18A3412E-2681-4D3A-A71B-7B9E4DE166E0Q33375461-5D8A9C9D-EFE3-4B0B-BBCC-5E088E61D366Q33382618-1FE7E03A-7942-4137-8BAA-0CB907B01431Q33395286-5BAAACA4-1180-4E0F-9BBE-0177796B7DA0Q33617237-D5859C8D-E156-4A98-B61F-471949C8DCC0Q33707455-14D2C134-C731-4E69-AB11-3C944665D4B7Q36051868-D5747116-C984-43AA-B811-EBCA5071D678Q36945183-B1C2E7DC-E6B9-44BB-8C14-9ED62E179D0BQ37001989-A68DF1A5-433F-44DA-9CB0-74CEB834AB77Q37127019-625FB300-030C-48C0-8DAA-868FFB5A6B30Q37723475-BB569137-2BAD-441A-B5CF-9E0C0DC5B05EQ38264923-294127CE-A02C-4831-8C77-F80AF4261292Q38773363-462061B7-909E-48B2-9794-66D2B3CFB75AQ38797384-C59A836D-1636-4F68-942E-162B76C40AB1Q39375290-42EDB218-EE41-4513-91B3-021E125CA0D6Q39527860-AB1C0D7D-EDAB-467D-98D1-2C347FD6917EQ40087182-A3977367-7C84-41C1-B675-620FCF65A72BQ40392491-BD0A5D4D-0CDF-4BA3-B4B4-B6113CA01A58Q40435003-BFCAABD2-644F-47F0-AE42-9F7A19FAF9BBQ40651796-3531C5E1-08AE-4989-BAAC-A02D99C7FCDFQ40950293-7D21B0A1-1B21-45B7-A6E4-9F50AED433D7Q41081977-43C784A0-0CEC-4D67-BC8E-828655E43C2FQ41252640-F5C3BEB3-F1F5-4EA4-8224-411DC1DAF747Q42127664-2D4C66A6-461A-44EB-B1B9-DD6DE1FFD2DAQ42285217-A267AB56-64B3-4D06-9BEB-D0FA21B87761Q43031147-21F727BD-B33C-4271-9E5E-FF32B5BC9D55Q43272252-774B979C-8EAC-47C1-AB06-42AB16E556A3Q44070048-F1E0100F-637F-409D-B8E6-7E4E474223EBQ45214615-EB6254F8-96D7-414F-A355-D4B6F7E07190Q45866178-B353DD84-B4B6-47D8-AD4A-A858A2BF8B33Q46020806-97F2D17E-CC9D-4B95-98A1-3EA2517E3BBFQ46266877-184D511F-9E34-4EE3-AC2C-6FD81610C906Q48137831-552EC616-EB8D-4AE0-8104-7E02A05DE926Q48155069-C11DAFC5-D64F-4198-A09E-DAB1725B3CFA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Zachary Hunter
@ast
Zachary Hunter
@en
Zachary Hunter
@es
Zachary Hunter
@nl
Zachary Hunter
@sl
type
label
Zachary Hunter
@ast
Zachary Hunter
@en
Zachary Hunter
@es
Zachary Hunter
@nl
Zachary Hunter
@sl
altLabel
Hunter ZR
@en
prefLabel
Zachary Hunter
@ast
Zachary Hunter
@en
Zachary Hunter
@es
Zachary Hunter
@nl
Zachary Hunter
@sl
P106
P31
P496
0000-0002-1689-1691